

LIST OF ABBREVIATIONS

Ab	:	Antibody
Akt	:	Protein Kinase B
ALT	:	Alanine aminotransferase
α-SMA	:	Alfa-smooth muscle actin
ASK	:	Apoptosis signal-regulating kinase
AST	:	Aspartate aminotransferase
AUC	:	Area under the curve
Bim	:	Bcl2-interacting mediator
<i>Cl3orf25</i>	:	Chromosome 13 open reading frame 25
CDK	:	Cyclin-dependent kinase 2
CHC	:	Chronic hepatitis C
CLDN1	:	Claudin
<i>c-Myc</i>	:	Cellular avian myelocytoma virus gene
CTGF	:	Connective tissue growth factor
CTL	:	Cytotoxic T lymphocytes
cvhRNAs	:	Competitive viral and host RNAs
DAAs	:	Direct-acting antivirals
DAB	:	3, 3' Diaminobenzidinetetrahydrochloride
DC	:	Dendritic cell
DNA	:	Deoxyribonucleic acid
E	:	Envelope
4E-BP1	:	Eukaryotic initiation factor 4E binding protein 1
ECM	:	Extracellular matrix
ELISA	:	Enzyme linked immunosorbant assay
ER	:	Endoplasmic reticulum
GGT	:	Gamma glutamyl transpeptidase
GI	:	Gastrointestinal
Hb	:	Hemoglobin
HBV	:	Hepatitis B virus
HCC	:	Hepatocellular carcinoma
HCV	:	Hepatitis C virus
HIF-1	:	Hypoxia-inducible transcription factor-1
HIV	:	Human immunodeficiency virus
HLA	:	Human leukocyte antigen
HMGCoA	:	3-hydroxy-3-methylglutaryl-coenzyme A
HRP	:	Horseshoe Peroxidase
HSC	:	Hepatic stellate cell
HVR	:	Hypervariable regions
IFN	:	Interferon
Ikk	:	Inhibitor of nuclear factor κ B kinase

IL	:	Interleukin
IKZF4	:	Ikaros Family Zinc Finger 4
IRES	:	Internal ribosome entry site
IRS-1	:	Insulin receptor substrate-1
MAPK	:	Mitogen-activated protein kinase
MIP	:	Macrophage inflammatory protein
miR	:	MicroRNA
MIR17HG	:	MicroRNA-17 host gene
MMP	:	Matrix metalloproteinase
mRNA	:	Messenger ribonucleic acid
mTOR	:	Mammalian target of rapamycin
MTP	:	Microsomal triglyceride transfer protein
MMAC1	:	Mutated in multiple advanced cancers 1
NAFLD	:	Non-alcoholic fatty liver disease
NFκB	:	Nuclear factor kappa B
NK	:	Natural killer
NS	:	Non-structural
nt	:	Nucleotides
p21	:	Cyclin-dependent kinase inhibitor CDKN1A
PI3K	:	Phosphoinositol 3-kinase
PIP2	:	Phosphatidylinositol-3,4-bisphosphate
PIP3	:	Phosphatidylinositol-3,4,5-triphosphate
PPARγ	:	Peroxisome proliferator-activated receptor-γ
pRB	:	Retinoblastoma protein
PT	:	Prothrombin time
PTEN	:	Phosphatase and tensin homolog
pre-miR	:	Precursor-miR
pri-miR	:	Primary-miR
RANTES	:	Regulated on activation normal T cell expressed and secreted
RASFs	:	Rheumatoid arthritis synovial fibroblasts
RdRp	:	RNA-dependent RNA polymerase
RISC	:	RNA-induced silencing complex
RNA	:	Ribonucleic acid

RNase	:	Ribonuclease
ROS	:	Reactive oxygen species
RT-PCR	:	Real time polymerase chain reaction
SD	:	Standard Deviation
SIRPα	:	Signal-regulatory protein α
SOCS	:	Suppressor of cytokine signaling
SREBP-1	:	Sterol regulatory element binding protein-1
STAT	:	Signal transducer and activator of transcription
TEP1	:	TGF- β -regulated and epithelial cell enriched phosphatase 1
TGF-β	:	Transforming growth factor beta
TGF-βRII	:	Transforming growth factor beta receptor II
Th	:	T helper
TLR	:	Toll-like receptor
TMB	:	Tetramethylbenzidine
TNF	:	Tumor necrosis factor
TNFAIP3	:	Tumor necrosis factor- α -induced protein 3
TRBP	:	Trans-activator RNA binding protein
Treg	:	T regulatory cells
TSP-1	:	Thrombospondin-1
UTR	:	Untranslated region

LIST OF TABLES

Table		Page
I.	Clinical and ultrasonographic data of patients with chronic hepatitis C virus (HCV) infection.	37
II.	Mean \pm SD and frequencies of clinical and ultrasonographic data of patients with chronic hepatitis C virus (HCV) infection.	39
III.	Laboratory and virological data of patients with chronic hepatitis C virus (HCV) infection.	40
IV.	Laboratory data of healthy subjects.	42
V.	Statistical comparisons between patients with chronic hepatitis C virus (HCV) infection and healthy subjects as regards laboratory data.	43
VI.	Plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels (pg/ml) in patients with chronic hepatitis C virus (HCV) infection and healthy subjects.	44
VII.	Histopathological findings in liver biopsies of patients with chronic hepatitis C virus (HCV) infection.	46
VIII.	Frequencies of histopathological findings in liver biopsies of patients with chronic hepatitis C virus (HCV) infection.	47
IX.	Immunohistochemical staining score of phosphatase and tensin homolog (PTEN) and nuclear factor-kappa B (NF- κ B) in liver biopsies of patients with chronic hepatitis C virus (HCV) infection.	48
X.	Frequencies of immunostaining score of phosphatase and tensin homolog (PTEN) and nuclear factor-kappa B (NF- κ B) in liver biopsies of patients with chronic hepatitis C virus (HCV) infection.	49
XI.	Statistical correlations (“r” value) between plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels, intrahepatic expression of phosphatase and tensin homolog (PTEN) and nuclear factor-kappa B (NF- κ B) and other parameters in patients with chronic hepatitis C virus (HCV) infection (n = 30).	53
XII.	Statistical comparisons between patients with chronic hepatitis C (CHC) infection and healthy subjects as regards plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels.	61
XIII.	Statistical comparisons between patients with chronic hepatitis C (CHC) and patients with cirrhosis as regards intrahepatic immunostaining score of phosphatase and tensin homolog (PTEN) and nuclear factor-kappa B (NF- κ B).	63

LIST OF FIGURES

Figure		Page
1.	Hepatitis C virus polyprotein.	1
2.	Hepatitis C virus internalization and release from hepatocyte.	4
3.	Natural history of HCV infection.	5
4.	(A.) Course of acute resolving hepatitis C and (B.) Course of acute hepatitis C that evolves into chronic infection.	6
5.	Schematic representation of microRNA biogenesis and target identification.	10
6.	Mechanisms of microRNA release from cells in the peripheral blood.	12
7.	Gene structure of human microRNA-17~92 and its homologues.	14
8.	Exon-intron structure of the <i>C13orf25</i> gene.	15
9.	Proposed mechanisms transcriptionally and post-transcriptionally regulating the microRNA-17~92 cluster.	16
10.	Specific targets of microRNA-17~92 cluster.	17
11.	Summary of the proposed functions of the microRNA-17~92 cluster.	18
12.	The structure of phosphatase and tensin homolog (PTEN).	22
13.	The standard curve of <i>MIR17HG</i> protein by ELISA.	30
14.	Statistical comparisons between patients with chronic hepatitis C virus infection and healthy subjects as regards plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels ($P = 0.012$).	45
15.	Receiver operating characteristic curve (ROC) shows that the sensitivity and specificity of the plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels in discriminating patients with chronic HCV infection from healthy subjects were 83.3% and 100% respectively at a cut-off level of 26.6 pg/ml (Area under the curve = 0.957).	45
16.	Distribution of immunostaining score of phosphatase and tensin homolog (PTEN) and nuclear factor-kappa B (NF-κB) in liver biopsies of patients with chronic hepatitis C virus (HCV) infection.	49
17.	Immunostaining of PTEN in chronic hepatitis C, METAVIR stage F1, with no steatosis. Strong brown positive staining of hepatocytes is seen (staining score 3) (anti-PTEN× 200).	50
18.	Immunostaining of PTEN in chronic hepatitis C. High power view demonstrating brown cytoplasmic as well as nuclear expression of the stain (anti-PTEN × 400).	50

Figure		Page
19.	Immunostaining of PTEN in hepatitis C virus-related cirrhosis, (METAVIR stage F4) and moderate steatosis, demonstrating weak PTEN expression (staining score 1) (anti-PTEN× 200).	51
20.	Immunostaining of nuclear factor-kappa B (NF-κB) in chronic hepatitis C. Brown positive nuclear staining is seen in some hepatocytes (arrows) (anti-NF-κB × 200).	51
21.	Immunostaining of nuclear factor-kappa B (NF-κB) in chronic hepatitis C. High power view demonstrating brown positive nuclear staining of hepatocytes (anti- NF-κB × 400).	52
22.	Statistical correlation between plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels and serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in patients with chronic hepatitis C virus (HCV) infection ($P = 0.014$ and $P = 0.036$ respectively).	54
23.	Statistical correlations between plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels and METAVIR histological activity grade and fibrosis stage in patients with chronic hepatitis C virus (HCV) infection ($P = 0.002$ and $P < 0.001$ respectively).	54
24.	Statistical correlations between plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels and steatosis grade in patients with chronic hepatitis C virus (HCV) infection ($P = 0.001$).	55
25.	Statistical correlation between plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels and intrahepatic phosphatase and tensin homolog (PTEN) expression in patients with chronic hepatitis C virus (HCV) infection ($P = 0.002$).	55
26.	Statistical correlation between plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels and intrahepatic nuclear factor-kappa B (NF-κB) expression in patients with chronic hepatitis C virus (HCV) infection ($P = 0.013$).	56
27.	Statistical correlation between intrahepatic phosphatase and tensin homolog (PTEN) expression and METAVIR histological activity grade in patients with chronic hepatitis C virus (HCV) infection ($P = 0.011$).	56
28.	Statistical correlation between intrahepatic phosphatase and tensin homolog (PTEN) expression and METAVIR fibrosis stage in patients with chronic hepatitis C virus (HCV) infection ($P = 0.003$).	57
29.	Statistical correlation between intrahepatic phosphatase and tensin homolog (PTEN) expression and steatosis grade in patients with chronic hepatitis C virus (HCV) infection ($P = 0.001$).	57

Figure		Page
--------	--	------

30.	Statistical correlation between intrahepatic nuclear factor-kappa B (NF-κB) expression and serum levels of aspartate aminotransferase (AST) in patients with chronic hepatitis C virus (HCV) infection ($P = 0.009$).	58
31.	Statistical correlation between intrahepatic nuclear factor-kappa B (NF-κB) expression and serum levels of alanine aminotransferase (ALT) in patients with chronic hepatitis C virus (HCV) infection ($P = 0.006$).	58
32.	Statistical correlation between intrahepatic nuclear factor-kappa B (NF-κB) expression and METAVIR histological activity grade in patients with chronic hepatitis C virus (HCV) infection ($P = 0.025$).	59
33.	Statistical correlation between intrahepatic nuclear factor-kappa B (NF-κB) expression and METAVIR fibrosis stage in patients with chronic hepatitis C virus (HCV) infection ($P = 0.004$).	59
34.	Statistical correlation between intrahepatic nuclear factor-kappa B (NF-κB) expression and steatosis grade in patients with chronic hepatitis C virus (HCV) infection ($P = 0.008$).	60
35.	Statistical correlation between intrahepatic expression of phosphatase and tensin homolog (PTEN) and nuclear factor-kappa B (NF-κB) in patients with chronic hepatitis C virus (HCV) infection ($P = 0.006$).	60
36.	Statistical comparisons between patients with chronic hepatitis C (CHC), patients with cirrhosis and healthy subjects as regards plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels ($P < 0.001$).	61
37.	Receiver operating characteristic curve (ROC) shows that the sensitivity and specificity of the plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels in discriminating patients with chronic hepatitis C from patients with cirrhosis were 100% and 88.9% respectively at a cut-off level of 45.5 pg/ml (Area under the curve = 0.995).	62
38.	Receiver operating characteristic curve (ROC) shows that the sensitivity and specificity of the plasma <i>microRNA-17 host gene (MIR17HG)</i> protein levels in discriminating patients with early fibrosis (METAVIR F1 or F2) from patients with advanced fibrosis (METAVIR F3 or F4) were 93.8% and 92.9% respectively at a cut-off level of 40.3 pg/ml (Area under the curve = 0.982).	62
39.	Statistical comparison between patients with chronic hepatitis C (CHC) and patients with cirrhosis as regards intrahepatic immunostaining score of phosphatase and tensin homolog (PTEN) ($P = 0.012$).	64
40.	Statistical comparison between patients with chronic hepatitis C (CHC) and patients with cirrhosis as regards intrahepatic immunostaining score of nuclear factor-kappa B (NF-κB) ($P =$	64
